| Similar Articles |
|---|
 |
The Motley Fool
April 16, 2011 |
Pozen Wins Injunction Blocking Generic Migraine Drug The ruling against Par Pharmaceutical comes just in time for Pozen.   |
The Motley Fool
February 24, 2011
Brian Orelli |
Youth in Revolt Against POZEN POZEN fails to get a pediatric extension on its migraine drug. |
The Motley Fool
April 17, 2008
Brian Orelli |
Headache Over for Pozen and Glaxo? The duo's FDA headache regarding their migraine drug is over, but a new one is about to begin. |
The Motley Fool
December 30, 2008
Brian Orelli |
2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers. |
The Motley Fool
December 16, 2011
Brian Orelli |
Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value. |
BusinessWeek
February 27, 2006
Gene G. Marcial |
Pozen's Trexima: Going To Market With Glaxo Pozen's Trexima is a new drug for severe headaches that analysts claim is more effective and faster-acting than GlaxoSmithKline's $1 billion-a-year blockbuster Imitrex. |
The Motley Fool
May 17, 2007
Mike Havrilla |
Pozen Poised for Profits The pharmaceutical reported first-quarter results. But investors should look to buy shares of this company because of how its results may look later this year. |
The Motley Fool
August 3, 2007
Brian Orelli |
Another Headache for Pozen Investors Drugmaker Pozen might have to run one more trial for the FDA for its migraine drug. |
The Motley Fool
October 8, 2007
Brian Orelli |
Pozen Submits Safety Data Will Pozen's response to its second approvable letter be enough? Investors may want to take this with a grain of salt. |
The Motley Fool
January 16, 2008
Brian Orelli |
Headache Almost Over for Pozen The drug is safe; hopefully that's all the FDA wanted to know. |
The Motley Fool
June 2, 2004
Roger Nusbaum |
POZEN Is a Poser Here's a great example of the riskiest type of biotech stock. |
The Motley Fool
September 17, 2011
Chris Seper |
Pozen's Digital Marketing Plan: A Prescription for the Pharma Industry? The company looks to get in tune with social media. |
The Motley Fool
August 3, 2006
S.J. Caplan |
AstraZeneca's Path to Avoid Pain The pharmaceutical giant partners with Pozen to co-develop a drug. Take heart, AstraZeneca shareholders! No queasy stomachs are expected in your future. |
The Motley Fool
November 18, 2009
Jennifer Schonberger |
Cleaning Up the Crisis MFS Investment Management chairman and author Bob Pozen discusses the current state of the economy. |
